Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial

Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial

Objectives: Macropinocytosis promotes internalization of albumin into cells to serve as a nutrient supply and is constitutively driven by signaling pathways frequently hyperactivated in head and neck squamous-cell carcinoma (HNSCC). In this way, drugs bound to albumin may selectively target HNSCC. n...

Full description

Bibliographic Details
Main Authors:	Adkins, D. (Author), Atiq, O. (Author), Gitau, M. (Author), Ley, J. (Author), Liu, J. (Author), Oppelt, P. (Author), Palka, K. (Author), Powell, S. (Author), Rigden, C. (Author), Spanos, W.C (Author)
Format:	Article
Language:	English
Published:	Elsevier Ltd 2021
Subjects:	130-nm albumin-bound paclitaxel acne adult aged Aged albuminoid Albumins anemia antineoplastic agent Antineoplastic Combined Chemotherapy Protocols Article aspartate aminotransferase aspartate aminotransferase blood level aspiration body weight disorder body weight loss cancer combination chemotherapy cancer growth cancer immunotherapy cancer patient cancer recurrence cancer survival carboplatin Carboplatin catheter infection cause of death cetuximab Cetuximab cisplatin clinical trial comorbidity coughing creatinine creatinine blood level diarrhea docetaxel dry skin durvalumab dysarthria dysgeusia dyspnea epistaxis fatigue female Female fluorouracil follow up Head and Neck Neoplasms head and neck squamous cell carcinoma Head and neck squamous-cell carcinoma head and neck tumor heart arrest hematuria hoarseness human Humans hypomagnesemia hypotension infusion reaction leukocyte disorder loading drug dose lung infection lymphocyte count lymphocytopenia maintenance chemotherapy major clinical study male Male metastasis Metastatic disease middle aged Middle Aged mitomycin mouth pain multicenter study multiple cycle treatment Nab-paclitaxel nanoparticle Nanoparticles nausea Neoplasm Recurrence, Local neutropenia neutrophil count nivolumab oral mucositis overall survival paclitaxel Paclitaxel pain palbociclib paronychia pathology pembrolizumab peripheral edema peripheral neuropathy phase 2 clinical trial platelet count priority journal progression free survival rash Recurrent disease respiratory failure sensory neuropathy sepsis side effect systemic therapy taxane derivative thrombocyte disorder thromboembolism tracheal hemorrhage trismus tumor pain tumor recurrence upper gastrointestinal bleeding
Online Access:	View Fulltext in Publisher

Similar Items

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
by: Thomas Chevalier, et al.
Published: (2021-06-01)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
by: Tomohiro Enokida, et al.
Published: (2020-03-01)

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
by: Vanita Noronha, et al.
Published: (2017-01-01)

Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study
by: Hui-Ching Wang, et al.
Published: (2020-09-01)

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study
by: Akash Mathur, et al.
Published: (2018-01-01)

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
by: Ammar Sukari, et al.
Published: (2015-04-01)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
by: Tomohiro Enokida, et al.
Published: (2018-08-01)

The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer
by: Alexander Rühle, et al.
Published: (2020-04-01)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
by: Kunal eSaigal, et al.
Published: (2014-06-01)

Recurrent squamous cell carcinoma of head and neck: results of treatment in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in 2012–2016
by: R. Yu. Karabut, et al.
Published: (2020-04-01)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
by: Sadamoto Zenda, et al.
Published: (2019-01-01)

Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
by: Hanan Shawky, et al.
Published: (2014-09-01)

Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer
by: Athanassios Argiris, et al.
Published: (2019-11-01)

DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY
by: R. Noviyani, et al.
Published: (2014-01-01)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01)

Incidence and risk factors of hypomagnesemia in head and neck cancer patients treated with cetuximab
by: Tomohiro Enokida, et al.
Published: (2016-09-01)

Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries.
by: Binu eMalhotra, et al.
Published: (2015-01-01)

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
by: Hana Starobova, et al.
Published: (2017-05-01)

miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas
by: János Tibor Fekete, et al.
Published: (2021-12-01)

The Value of Laboratory Parameters for Anemia, Renal Function, Systemic Inflammation and Nutritional Status as Predictors for Outcome in Elderly Patients with Head-and-Neck Cancers
by: Alexander Rühle, et al.
Published: (2020-06-01)

Immunotherapy in head and neck cancer: aiming at EXTREME precision
by: Petr Szturz, et al.
Published: (2017-06-01)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
by: Shinya Uozumi, et al.
Published: (2018-12-01)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
by: Junji Tsurutani, et al.
Published: (2021-02-01)

A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine
by: Jens K. D. Bentzen, et al.
Published: (2018-06-01)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
by: Emmanuel Seront, et al.
Published: (2019-03-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

A case of palatal adenoid cystic carcinoma with late recurrence
by: Dixa B Thakrar, et al.
Published: (2017-04-01)

Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer
by: Waseem Abbas, et al.
Published: (2021-04-01)

High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option
by: Rajendra Bhalavat, et al.
Published: (2018-10-01)

The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers–In Vitro Studies
by: Bianka Gurbi, et al.
Published: (2019-11-01)

Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
by: Jacques Bernier
Published: (2011-12-01)

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
by: Muge Akmansu, et al.
Published: (2010-12-01)

Type of chemotherapy has substantial effects on the immune system in ovarian cancer
by: Ann Vankerckhoven, et al.
Published: (2021-06-01)

Chemotherapy-induced neuropathic pain characteristics in Mexico’s National Cancer Center pain clinic
by: Coffeen U, et al.
Published: (2019-05-01)

A 10 year data analysis of lymphatic system metastasis and recurrence in individuals affected by malignant tumors within the oral cavity and maxillofacial region
by: Adam Dreksler, et al.
Published: (2015-09-01)

A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery
by: Julianna Rodin, et al.
Published: (2018-10-01)

High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment
by: Zuping Zhang, et al.
Published: (2019-10-01)

De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers—HPV and Beyond
by: Alexander Rühle, et al.
Published: (2021-05-01)

Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer
by: Jiying Yang, et al.
Published: (2017-01-01)

Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume
by: Linda Nissi, et al.
Published: (2021-03-01)